• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吉非贝齐对不同类型高脂蛋白血症患者脂蛋白浓度的影响。

Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia.

作者信息

Olsson A G, Rössner S, Walldius G, Carlson L A

出版信息

Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):28-31. doi: 10.1177/00359157760690S207.

DOI:10.1177/00359157760690S207
PMID:190607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1864039/
Abstract

The lipoprotein lowering effect of gemfibrozil, 400 mg twice daily, was studied for 24 weeks in 26 subjects with primary hyperlipoproteinaemia (type IIa, 5; IIb, 3; III, 3; and IV, 15). Maximum effects were noted after four weeks on very low density lipoproteins (VLDL) and after 12 weeks on low density lipoproteins (LDL), these effects remaining throughout the study. Gemfibrozil decreased VLDL triglycerides (TG) in all types of hyperlipoproteinaemia according to the equation: deltaVLDL TG (mmol/l) = -0.80 X initial VLDL TG concentration + 0.68 The drug affected the low density lipoprotein (LDL) cholesterol= -0.45 X initial LDL cholesterol + 61 This means that LDL cholesterol on average decreased if the initial LDL concentration was above 135 mg/100 ml and increased below that concentration. LDL TG and high density lipoprotein (HDL) TG concentrations also decreased significantly. A slight increase in HDL cholesterol concentration occurred after administration of gemfibrozil. Two subjects had to stop treatment because of nausea and abdominal pain respectively, attributed to the drug. No biochemical side effects were noted.

摘要

对26例原发性高脂蛋白血症患者(IIa型5例、IIb型3例、III型3例、IV型15例)进行了一项研究,给予吉非贝齐每日两次、每次400mg,疗程24周,以观察其降低脂蛋白的效果。四周时观察到对极低密度脂蛋白(VLDL)的最大效应,12周时观察到对低密度脂蛋白(LDL)的最大效应,且这些效应在整个研究过程中持续存在。吉非贝齐可根据以下公式降低所有类型高脂蛋白血症患者的VLDL甘油三酯(TG):ΔVLDL TG(mmol/l)=-0.80×初始VLDL TG浓度+0.68。该药物对低密度脂蛋白(LDL)胆固醇的影响为=-0.45×初始LDL胆固醇+61。这意味着,如果初始LDL浓度高于135mg/100ml,LDL胆固醇平均会降低;低于该浓度则会升高。LDL TG和高密度脂蛋白(HDL)TG浓度也显著降低。服用吉非贝齐后,HDL胆固醇浓度略有升高。两名受试者分别因恶心和腹痛而不得不停止治疗,原因归咎于该药物。未观察到生化方面的副作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c77e/1864039/b5c6b15d4c85/procrsmed00035-0035-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c77e/1864039/b5c6b15d4c85/procrsmed00035-0035-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c77e/1864039/b5c6b15d4c85/procrsmed00035-0035-a.jpg

相似文献

1
Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia.吉非贝齐对不同类型高脂蛋白血症患者脂蛋白浓度的影响。
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):28-31. doi: 10.1177/00359157760690S207.
2
Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.吉非贝齐:对原发性高甘油三酯血症患者血清脂质、脂蛋白、肝素后血浆脂肪酶活性及葡萄糖耐量的影响
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):58-63. doi: 10.1177/00359157760690S215.
3
Gemfibrozil treatment: a comparison with clofibrate.
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):88-9. doi: 10.1177/00359157760690S222.
4
Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.吉非贝齐作为高脂血症的降脂化合物。一项安慰剂对照交叉试验。
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):32-7. doi: 10.1177/00359157760690S208.
5
The evaluation of lipoprotein changes during gemfibrozil treatment.吉非贝齐治疗期间脂蛋白变化的评估。
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):76-7. doi: 10.1177/00359157760690S218.
6
The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.吉非贝齐与安慰剂和氯贝丁酯治疗高脂蛋白血症的比较。
N Z Med J. 1980 Nov 12;92(671):345-9.
7
A long-term trial of gemfibrozil in the treatment of hyperlipidaemias.吉非贝齐治疗高脂血症的长期试验。
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):49-52. doi: 10.1177/00359157760690S213.
8
Studies in asymptomatic primary hyperlipidaemia. IV. ECG at rest and during exercise and its relation to various lipoprotein classes.无症状原发性高脂血症的研究。IV. 静息及运动时的心电图及其与各种脂蛋白类别的关系。
Acta Med Scand. 1975 Jul-Aug;198(1-2):55-73.
9
Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.吉非贝齐对高甘油三酯血症患者血浆脂蛋白 - 载脂蛋白分布及血小板反应性的影响。
J Lab Clin Med. 1987 Sep;110(3):279-86.
10
The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report.
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):78-9. doi: 10.1177/00359157760690S219.

引用本文的文献

1
Use of fibrates in the metabolic syndrome: A review.贝特类药物在代谢综合征中的应用:综述
World J Diabetes. 2016 Mar 10;7(5):74-88. doi: 10.4239/wjd.v7.i5.74.
2
Mechanism of action of gemfibrozil on lipoprotein metabolism.吉非贝齐对脂蛋白代谢的作用机制。
J Clin Invest. 1985 May;75(5):1702-12. doi: 10.1172/JCI111879.
3
Adverse effects of hypolipidaemic drugs.降血脂药物的不良反应。

本文引用的文献

1
Classification of hyperlipidaemias and hyperlipoproteinaemias.高脂血症和高脂蛋白血症的分类。
Bull World Health Organ. 1970;43(6):891-915.
Med Toxicol. 1987 Jan-Feb;2(1):10-32. doi: 10.1007/BF03259858.
4
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.正常、IIa型、III型和IV型高脂蛋白血症个体餐后脂蛋白代谢的不同模式。考来烯胺和吉非贝齐治疗的效果。
J Clin Invest. 1987 Apr;79(4):1110-9. doi: 10.1172/JCI112926.
5
Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.吉非贝齐。对其药效学和药代动力学特性以及在血脂异常治疗中的应用综述。
Drugs. 1988 Sep;36(3):314-39. doi: 10.2165/00003495-198836030-00004.
6
HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.高密度脂蛋白胆固醇作为冠心病的一个风险因素。赫尔辛基心脏研究的最新进展。
Drugs. 1990;40 Suppl 1:7-12. doi: 10.2165/00003495-199000401-00004.